Trial Profile
A Phase 2 Study Evaluating the Efficacy of the Farnesyl Transferase Inhibitor (FTI) R115777 in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2008
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 28 Sep 2006 New trial record.